Brett Monia, Ionis Pharmaceuticals CEO

Io­n­is hands off an an­ti­sense drug for kid­ney dis­ease, giv­ing all rights to Roche

Io­n­is is hand­ing Roche a drug on the cusp of Phase III.

Io­n­is an­nounced ear­ly Mon­day that Roche is in-li­cens­ing and ad­vanc­ing the an­ti­sense drug can­di­date known as IO­N­IS-FB-LRx in­to a Phase III clin­i­cal study. The drug is be­ing in­ves­ti­gat­ed for im­munoglob­u­lin A nephropa­thy (IgAN), a kid­ney dis­ease that can lead to re­nal fail­ure. The dis­ease is marked by im­munoglob­u­lin A buildup in the kid­neys, re­sult­ing in in­flam­ma­tion and ul­ti­mate­ly kid­ney fail­ure if left un­treat­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.